Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

- PMLiVE

NICE recommends MSD’s diabetes drug Steglatro

MSD offering lowest price to win share of SGLT-2 inhibitor market

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

Suggests Orkambi row has undermined confidence in NICE process

AstraZeneca AZ

AZ to address Imfinzi setback, but sees potential with Tagrisso

Pharma giant to deliver oncology pipeline update at AACR

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

Biomarin

NICE knocks back BioMarin’s Batten disease drug

£500,000 list price too high without long-term data, says watchdog

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links